- Home
- SDGR vs DNLI Comparison
SDGR vs DNLI Comparison
Compare SDGR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- DNLI
- Stock Information
- Founded
- SDGR 1990
- DNLI 2013
- Country
- SDGR United States
- DNLI United States
- Employees
- SDGR N/A
- DNLI N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDGR Health Care
- DNLI Health Care
- Exchange
- SDGR Nasdaq
- DNLI Nasdaq
- Market Cap
- SDGR 1.7B
- DNLI 1.9B
- IPO Year
- SDGR 2020
- DNLI 2017
- Fundamental
- Price
- SDGR $21.62
- DNLI $13.24
- Analyst Decision
- SDGR Buy
- DNLI Strong Buy
- Analyst Count
- SDGR 5
- DNLI 15
- Target Price
- SDGR $32.80
- DNLI $33.85
- AVG Volume (30 Days)
- SDGR 1.2M
- DNLI 1.3M
- Earning Date
- SDGR 05-07-2025
- DNLI 05-06-2025
- Dividend Yield
- SDGR N/A
- DNLI N/A
- EPS Growth
- SDGR N/A
- DNLI N/A
- EPS
- SDGR N/A
- DNLI N/A
- Revenue
- SDGR $230,492,000.00
- DNLI N/A
- Revenue This Year
- SDGR $24.71
- DNLI N/A
- Revenue Next Year
- SDGR $17.64
- DNLI $256.73
- P/E Ratio
- SDGR N/A
- DNLI N/A
- Revenue Growth
- SDGR 22.29
- DNLI N/A
- 52 Week Low
- SDGR $16.60
- DNLI $10.57
- 52 Week High
- SDGR $28.47
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SDGR 41.07
- DNLI 41.80
- Support Level
- SDGR $21.13
- DNLI $12.86
- Resistance Level
- SDGR $22.00
- DNLI $13.77
- Average True Range (ATR)
- SDGR 1.03
- DNLI 0.75
- MACD
- SDGR -0.23
- DNLI -0.11
- Stochastic Oscillator
- SDGR 30.11
- DNLI 14.07
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.